LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

Search

Corvus Pharmaceuticals Inc

Fermé

3.87 -4.68

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.87

Max

4.04

Chiffres clés

By Trading Economics

Revenu

28M

-12M

BPA

-0.138

Employés

31

EBITDA

-851K

-8.1M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+242.67% upside

Dividendes

By Dow Jones

Prochains Résultats

5 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

3.3M

276M

Ouverture précédente

8.55

Clôture précédente

3.87

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 mai 2025, 23:20 UTC

Résultats

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

13 mai 2025, 23:48 UTC

Market Talk

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

13 mai 2025, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 mai 2025, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

13 mai 2025, 23:24 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

13 mai 2025, 23:24 UTC

Market Talk
Résultats

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

13 mai 2025, 22:58 UTC

Résultats

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 mai 2025, 22:58 UTC

Résultats

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 mai 2025, 22:58 UTC

Résultats

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

13 mai 2025, 22:58 UTC

Résultats

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

13 mai 2025, 22:38 UTC

Résultats

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

13 mai 2025, 22:38 UTC

Résultats

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

13 mai 2025, 22:37 UTC

Résultats

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

13 mai 2025, 22:36 UTC

Résultats

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

13 mai 2025, 22:35 UTC

Résultats

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

13 mai 2025, 22:34 UTC

Résultats

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

13 mai 2025, 22:33 UTC

Résultats

Aristocrat: Interactive Business Delivered Strong Revenue Growth

13 mai 2025, 22:33 UTC

Résultats

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

13 mai 2025, 22:33 UTC

Résultats

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

13 mai 2025, 22:30 UTC

Résultats

Aristocrat Interim Dividend 44 Australian Cents/Share

13 mai 2025, 22:30 UTC

Résultats

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

13 mai 2025, 22:29 UTC

Résultats

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

13 mai 2025, 22:28 UTC

Résultats

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

13 mai 2025, 21:15 UTC

Résultats

Nu Holdings 1Q Rev $3.2B >NU

13 mai 2025, 21:03 UTC

Actualités

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

13 mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13 mai 2025, 20:32 UTC

Résultats

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13 mai 2025, 20:31 UTC

Résultats

Alcon 1Q Sales $2.45B >ALC.EB

13 mai 2025, 20:30 UTC

Résultats

Alcon 1Q Rev $2.47B >ALC.EB

13 mai 2025, 20:30 UTC

Résultats

Alcon 1Q EPS 70c >ALC.EB

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

242.67% hausse

Prévisions sur 12 Mois

Moyen 13.33 USD  242.67%

Haut 17 USD

Bas 11 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

3 ratings

3

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

3.165 / 3.5827Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.